KLK3 and prostate cancer: In order to test for possible differences in the tumours’ spatial architectures, we fitted the ABM to these same data, which consist of monthly PSA measurements of 65 patients undergoing intermittent androgen deprivation treatment for recurrent, locally advanced prostate cancer.